Pembrolizumab in adjuvant therapy in non-small cell lung cancers
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:111 |
|---|---|
| Enthalten in: |
Bulletin du cancer - 111(2024), 4 vom: 07. März, Seite 334-336 |
| Sprache: |
Französisch |
|---|
| Weiterer Titel: |
Pembrolizumab en adjuvant dans le cancer bronchique non à petites cellules |
|---|
| Beteiligte Personen: |
Lefèvre, Antoine [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 26.03.2024 Date Revised 26.03.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.bulcan.2023.12.012 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM36961710X |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM36961710X | ||
| 003 | DE-627 | ||
| 005 | 20240326235828.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240313s2024 xx |||||o 00| ||fre c | ||
| 024 | 7 | |a 10.1016/j.bulcan.2023.12.012 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1349.xml |
| 035 | |a (DE-627)NLM36961710X | ||
| 035 | |a (NLM)38471995 | ||
| 035 | |a (PII)S0007-4551(24)00047-X | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a fre | ||
| 100 | 1 | |a Lefèvre, Antoine |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Pembrolizumab in adjuvant therapy in non-small cell lung cancers |
| 246 | 3 | 3 | |a Pembrolizumab en adjuvant dans le cancer bronchique non à petites cellules |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 26.03.2024 | ||
| 500 | |a Date Revised 26.03.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 650 | 4 | |a Letter | |
| 650 | 4 | |a Adjuvant therapy | |
| 650 | 4 | |a Cancer bronchique non à petites cellules | |
| 650 | 4 | |a Immunotherapy | |
| 650 | 4 | |a Immunothérapie | |
| 650 | 4 | |a Non-small cell lung cancer | |
| 650 | 4 | |a Pembrolizumab | |
| 650 | 4 | |a Traitement adjuvant | |
| 650 | 7 | |a pembrolizumab |2 NLM | |
| 650 | 7 | |a DPT0O3T46P |2 NLM | |
| 650 | 7 | |a Antibodies, Monoclonal, Humanized |2 NLM | |
| 650 | 7 | |a Nivolumab |2 NLM | |
| 650 | 7 | |a 31YO63LBSN |2 NLM | |
| 700 | 1 | |a Tissot, Claire |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Bulletin du cancer |d 1966 |g 111(2024), 4 vom: 07. März, Seite 334-336 |w (DE-627)NLM000155853 |x 1769-6917 |7 nnns |
| 773 | 1 | 8 | |g volume:111 |g year:2024 |g number:4 |g day:07 |g month:03 |g pages:334-336 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.bulcan.2023.12.012 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 111 |j 2024 |e 4 |b 07 |c 03 |h 334-336 | ||